首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
【24h】

Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials

机译:在高风险患者中达到靶血压(120-140mmHg)和心血管结果的舒张压和脉冲压力:Ontarget和Transcend试验的结果

获取原文
获取原文并翻译 | 示例
       

摘要

Aims Current guidelines of hypertensive management recommend upper limits for systolic (SBP) and diastolic blood pressure (DBP). J-curve associations of BP with risk exist for some outcomes suggesting that lower limits of DBP goals may also apply. We examined the association between mean attained DBP and cardiovascular (CV) outcomes in patients who achieved an on-treatment SBP in the range of 120 to 140 mmHg in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease (TRANSCEND) trials on patients with high CV risk. This SBP range was associated with the lowest CV risk.
机译:AIMS高血压管理指南建议收缩期(SBP)和舒张压(DBP)的上限。 有一些结果的BP具有风险的J-Curve关联,表明DBP目标的较低限制也可能适用。 我们检查了在持续的替代赛中,在120至140 mmHg的患者中达到了在持续的替代赛的患者的患者中达到了患者的平均dBP和心血管(CV)结果之间的关联。 Ace Itce患者心血管疾病(超越)试验高CV风险患者的临床随机评估研究。 该SBP范围与最低的CV风险相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号